Oral contraceptive use and conotruncal congenital heart disease
Abstract
Background Congenital heart disease (CHD) represents some of the more prevalent malformations among live births and remains the leading cause of death from congenital malformations. Conotruncal anomalies comprise a diverse group of CHD involving the outflow tracts of the heart and the great vessels. Oral contraceptive exposure before pregnancy may be one of the risk factors for conotruncal CHD.
Objective To evaluate the effect of oral contraceptive use before pregnancy on the risk of conotruncal CHD in children.
Methods A case-control study was conducted from July 2010 until July 2011 in Haji Adam Malik Hospital, Medan. Subjects with CHD were divided into two groups: conotruncal CHD as the case group and non-conotruncal CHD as the control group. Both groups had mothers with and without histories of oral contraceptive use before pregnancy. Parents were interviewed using questionnaires. Statistical analyses were performed using Chi-square test, student’s T-test, and Mann Whitney test. Results A total of 80 subjects were eligible, with 40 subjects in each group. The percentages of subjects whose mothers used oral contraceptives were 62% of the conotruncal CHD group and 60% of the non-conotruncal CHD group (OR 0.82; 95%CI 0.33 to 1.98). The mean duration of maternal oral contraceptive use before pregnancy was 19.1 months for the case group and 18.8
months for the control group (P=0.87).
Conclusion In children with CHD, maternal oral contraceptive use before pregnancy does not appear to increase the risk of conotruncal CHD.
References
2. Baziad A. Kontrasepsi hormonal. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2002. p. 1-50.
3. The American College of Obstetricians and Gynacologists Committee. Contraceptives and congenital anomalies. Int J Gynecol Obstet. 1993;42:316-7.
4. Malik S, Cleves MA, Zhao W, Correa A, Hobbs CA. Association between congenital heart disease and small for gestational age. Pediatrics. 2007;119:e976-82.
5. Bernstein D. The cardiovascular system. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders Elsevier; 2007. p. 1851-4.
6. The Executive of the Society of Obstetricians and Gynecologists of Canada. Principles of human teratology: drug, chemical, and infectious exposure. J Obstet Gynecol Com. 2007;199:911-6.
7. Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol. 2003;24:195-221.
8. Harris JA, Francannet C, Pradat P, Robert E. The epidemiology of cardiovascular defects, part 2: a study based on data from three large registries of congenital malformations. Pediatr Cardiol. 2003;24:222-35.
9. Goldmuntz E, Clark BJ, Mitchell LE, Jawad AF, Cuneo BF, Reed L, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol. 1998;32:492-8.
10. Reefhuis J, Honein MA. Maternal age and non-chromosomal birth defects, Atlanta 1968-2000: teenager or thirtysomething, who is at risk? Birth Defects Res A Clin Mol Teratol. 2004;70:572-9.
11. Carmichael SL, Ma C, Shaw GM. Socioeconomic measures, orofacial clefts, and conotruncal heart defects in California. Birth Defects Res A Clin Mol Teratol. 2009;85:850-7.
12. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107:32.
13. Adams MM, Mulinare J, Dooley K. Risk factors for conotruncal cardiac defects in Atlanta. J Am Coll Cardiol. 1989;14:432-42.
14. De Santis MD, Cavaliere AF, Straface G, Carducci B, Caruso A. Failure of emergency contraceptive levonorgestrel and the risk of adverse effects in pregnancy and on fetal development: an observational cohort study. Fertil Steril. 2005;84:296-9.
15. Pizzo TSD, Sanseverino MTV, Mengue SS. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad Saude Publica. 2008;24:1447- 53.
16. Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P. Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod. 2000;15:129- 48.
17. Fisher B, Rose NC, Carey JC. Principles and practice of teratology for the obstetrician. Clin Obstet Gynecol. 2008;51:106-18.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2017-02-01
Published 2014-12-30